Of note, neurological toxicities of repotrectinib (and entrectinib) are attributed to the inhibition of TRK, which is widely expressed and involved in the central and peripheral nervous systems.2 Based on TRIDENT-1, the FDA approved repotrectinib in 2023 for line-agnostic treatment for locally advanced or metastatic ROS1+ NSCLC.43 The gene discussed is ROS1; the disease is non-small cell lung carcinoma.